According to Securities Star News, as of the close of trading on May 17, 2024, Nuotai Biotech (688076) closed at 56.8 yuan, down 1.22%, with a turnover rate of 1.59%, a volume of 23,300 contracts and a turnover of 132 million yuan.
In terms of capital flow data on May 17, the net outflow of main funds was 8.2715 million yuan, accounting for 6.26% of the total turnover, the net inflow of floating funds was 1.4606 million yuan, accounting for 1.11% of the total turnover, and the net inflow of retail funds was 6.8109 million yuan, accounting for 5.16% of the total turnover.
The list of capital flows in the past 5 days is shown in the following table:
According to the financing information of Nuotai Bio, in terms of financing, the financing purchase on the same day was 5.6418 million yuan, the financing repayment was 6.0837 million yuan, and the net financing repayment was 441,900 yuan. In terms of securities lending, 700.0 shares were sold by securities borrowing, 300.0 shares were repaid by securities borrowing, 16,500 shares were borrowed and borrowed, and the balance of securities borrowing and lending was 937,500 yuan. The balance of margin financing and securities lending was 161 million yuan. See the following table for a list of margin trading data in the past 5 days:
The main indicators and industry rankings of the stock are as follows:
According to the first quarter report of Nuotai Biotech in 2024, the company's main revenue was 356 million yuan, an increase of 71.02% year-on-year; the net profit attributable to the parent company was 66.3268 million yuan, an increase of 215.65% year-on-year; deducted non-net profit of 65.3985 million yuan, an increase of 179.69% year-on-year; The debt ratio was 39.01%, the investment income was 173,500 yuan, the financial expenses were 3,245,300 yuan, and the gross profit margin was 67.26%. The main business of Nuotai Biotech (688076): customized product business and independent product business, of which customized product business includes CDMO business, CMO business and CRO business; Independent selection of products refers to the company's focus on the treatment of diabetes, cardiovascular diseases, tumors and other diseases, focusing on peptide drugs, supplemented by small molecule chemical drugs, independently selecting generic drugs with high technical barriers and good market prospects, and actively organizing R&D, production, registration and sales.
A total of 16 institutions have rated the stock in the last 90 days, 14 have given buy ratings and 2 have overweight ratings. The average institutional price target over the last 90 days is 54.96.
Explanation of the term capital flow: It refers to the reversal of the flow of funds through price changes. When the stock price is rising, the turnover generated by the active buy order is the force that drives the stock price up, which is defined as the inflow of funds, and the turnover generated by the active sell order when the stock price is in a falling state is the force that pushes the stock price down, and this part of the turnover is defined as the outflow of funds. The difference between the two on the day is the net force that is left to push the stock price up after the two forces offset on that day. The main capital flow, floating capital flow and retail capital flow are calculated by the transaction amount of each transaction order.
Note: The main funds are extra-large single transactions, the floating capital is large single transactions, and the retail investors are small and medium-sized single transactions
The above content is compiled by Securities Star based on public information, generated by an algorithm (Network Information Calculation No. 310104345710301240019), and has nothing to do with the position of this site, if there is a problem with the data, please contact us. This article is a compilation of data and does not constitute any investment advice for you, investment is risky, please make a cautious decision.